{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T03:06:03Z","timestamp":1790910363607,"version":"4.1.0"},"reference-count":73,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T00:00:00Z","timestamp":1740441600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T00:00:00Z","timestamp":1740441600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["Project Grant (PJT-178132)"],"award-info":[{"award-number":["Project Grant (PJT-178132)"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000245","name":"Michael Smith Health Research BC","doi-asserted-by":"publisher","award":["Scholar Award (#18286)"],"award-info":[{"award-number":["Scholar Award (#18286)"]}],"id":[{"id":"10.13039\/501100000245","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"crossref","award":["NRF-2021R1A6A1A03038899"],"award-info":[{"award-number":["NRF-2021R1A6A1A03038899"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BioDrugs"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1007\/s40259-025-00709-1","type":"journal-article","created":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T05:02:06Z","timestamp":1740459726000},"page":"461-476","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Biosimilar Policies and Their Impact on Market Penetration of Adalimumab, Etanercept and Infliximab: A Policy Synthesis and Descriptive Analysis in 13 OECD Countries"],"prefix":"10.1007","volume":"39","author":[{"given":"Alexander C. T.","family":"Tam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasleen","family":"Badesha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daphne P.","family":"Guh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick","family":"Bansback","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin K.","family":"Peter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aidan","family":"Hollis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Grootendorst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang-Cheol","family":"Bae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aslam H.","family":"Anis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7988-1979","authenticated-orcid":false,"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,25]]},"reference":[{"key":"709_CR1","unstructured":"Biosimilar medicines: overview | European Medicines Agency. https:\/\/www.ema.europa.eu\/en\/human-regulatory-overview\/biosimilar-medicines-overview. Accessed 3 Jan 2024."},{"key":"709_CR2","unstructured":"Biosimilars | FDA. https:\/\/www.fda.gov\/drugs\/therapeutic-biologics-applications-bla\/biosimilars. Accessed 3 Jan 2024."},{"key":"709_CR3","doi-asserted-by":"crossref","unstructured":"Biosimilars: what clinicians should know | Blood | American Society of Hematology. https:\/\/ashpublications.org\/blood\/article\/120\/26\/5111\/30935\/Biosimilars-what-clinicians-should-know. Accessed 3 Jan 2024.","DOI":"10.1182\/blood-2012-04-425744"},{"issue":"3\u20134","key":"709_CR4","doi-asserted-by":"publisher","first-page":"120","DOI":"10.5639\/gabij.2012.0103-4.036","volume":"1","author":"R Haustein","year":"2012","unstructured":"Haustein R, de Millas C, H\u00f6er A, H\u00e4ussler B. Saving money in the European healthcare systems with biosimilars. Generics Biosimilars Initiat J. 2012;1(3\u20134):120\u20136. https:\/\/doi.org\/10.5639\/gabij.2012.0103-4.036.","journal-title":"Generics Biosimilars Initiat J."},{"key":"709_CR5","unstructured":"Troein P, Newton M, Stoddart K, Arias A. The impact of biosimilar competition in Europe 2022. https:\/\/www.iqvia.com\/-\/media\/iqvia\/pdfs\/library\/white-papers\/the-impact-of-biosimilar-competition-in-europe-2022.pdf."},{"key":"709_CR6","unstructured":"Prescribed drug spending in Canada, 2022 | CIHI. https:\/\/www.cihi.ca\/en\/prescribed-drug-spending-in-canada-2022. Accessed 8 Apr 2024."},{"key":"709_CR7","unstructured":"Adalimumab expenditures in countries with and without available biosimilars. Center for Biosimilars. March 16, 2024. https:\/\/www.centerforbiosimilars.com\/view\/adalimumab-expenditures-in-countries-with-and-without-available-biosimilars. Accessed 30 Aug 2024."},{"issue":"4","key":"709_CR8","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.therap.2021.10.012","volume":"77","author":"Q Jarrion","year":"2022","unstructured":"Jarrion Q, Azzouz B, Robinson J, Jolly D, Vallet C, Trenque T. Penetration rate of anti-TNF biosimilars and savings at 5 years after their introduction in French hospitals. Therapies. 2022;77(4):467\u201375. https:\/\/doi.org\/10.1016\/j.therap.2021.10.012.","journal-title":"Therapies"},{"key":"709_CR9","doi-asserted-by":"crossref","unstructured":"Moorkens E, Jonker-Exler C, Huys I, Declerck P, Simoens S, Vulto AG. Overcoming barriers to the market access of biosimilars in the European Union: the case of biosimilar monoclonal antibodies. Front Pharmacol. 2016;7. https:\/\/www.frontiersin.org\/journals\/pharmacology\/articles\/10.3389\/fphar.2016.00193. Accessed 23 Feb 2024.","DOI":"10.3389\/fphar.2016.00193"},{"key":"709_CR10","unstructured":"Arad N, Staton E, Lopez MH, Goriola S, McClellan M, Richman B. Realizing the benefits of biosimilars: overcoming rebate walls. Duke University; 2022. https:\/\/healthpolicy.duke.edu\/sites\/default\/files\/2022-03\/Biosimilars%20-%20Overcoming%20Rebate%20Walls.pdf."},{"key":"709_CR11","unstructured":"Arad N, Lopez MH, Ray R, et al. Realizing the benefits of biosimilars: what the U.S. Can learn from Europe. Duke University; 2021. https:\/\/healthpolicy.duke.edu\/sites\/default\/files\/2021-04\/Realizing%20the%20Benefits%20of%20Biosimilars.pdf. Accessed 23 Feb 2024."},{"issue":"8","key":"709_CR12","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.18553\/jmcp.2021.27.8.1129","volume":"27","author":"BS Edgar","year":"2021","unstructured":"Edgar BS, Cheifetz AS, Helfgott SM, et al. Overcoming barriers to biosimilar adoption: real-world perspectives from a national payer and provider initiative. J Manag Care Spec Pharm. 2021;27(8):1129\u201335. https:\/\/doi.org\/10.18553\/jmcp.2021.27.8.1129.","journal-title":"J Manag Care Spec Pharm"},{"issue":"1","key":"709_CR13","doi-asserted-by":"publisher","first-page":"1307315","DOI":"10.1080\/20016689.2017.1307315","volume":"5","author":"C R\u00e9muzat","year":"2017","unstructured":"R\u00e9muzat C, Kapu\u015bniak A, Caban A, et al. Supply-side and demand-side policies for biosimilars: an overview in 10 European member states. J Mar Access Health Policy. 2017;5(1):1307315. https:\/\/doi.org\/10.1080\/20016689.2017.1307315.","journal-title":"J Mar Access Health Policy."},{"key":"709_CR14","unstructured":"e Patented Medicine Prices Review Board. Biologics in Canada Part 1: market trends 2018. May 2020. https:\/\/www.canada.ca\/content\/dam\/pmprb-cepmb\/documents\/reports-and-studies\/chartbooks\/biologics-part1-market-trends.pdf. Accessed 8 Apr 2024."},{"key":"709_CR15","unstructured":"Canada PMPRB. Canada\u2019s evolving market for biosimilars and what it means for payers. May 16, 2022. https:\/\/www.canada.ca\/en\/patented-medicine-prices-review\/services\/npduis\/analytical-studies\/posters\/evolving-market-biosimilars-payers.html. Accessed 8 Apr 2024."},{"key":"709_CR16","unstructured":"List of OECD member countries\u2014ratification of the convention on the OECD. https:\/\/www.oecd.org\/about\/document\/ratification-oecd-convention.htm. Accessed 30 Apr 2024."},{"key":"709_CR17","unstructured":"Government of Canada PW and GSC. Canada Gazette, Part 2, Volume 153, Number 17: regulations amending the patented medicines regulations (additional factors and information reporting requirements). August 21, 2019. https:\/\/canadagazette.gc.ca\/rp-pr\/p2\/2019\/2019-08-21\/html\/sor-dors298-eng.html. Accessed 30 Apr 2024."},{"key":"709_CR18","unstructured":"Canada PMPRB. Potential sources for foreign prices: PMPRB11. July 5, 2022. https:\/\/www.canada.ca\/en\/patented-medicine-prices-review\/services\/are-you-patentee\/potential-sources-foreign-prices.html. Accessed 30 Apr 2024."},{"key":"709_CR19","unstructured":"Available IQVIA Data. https:\/\/www.iqvia.com\/insights\/the-iqvia-institute\/available-iqvia-data. Accessed 22 Jan 2024."},{"key":"709_CR20","unstructured":"MIDAS\u00ae. https:\/\/www.iqvia.com\/solutions\/commercialization\/brand-strategy-and-management\/market-measurement\/midas. Accessed 22 Jan 2024."},{"key":"709_CR21","unstructured":"World Health Organization Collaborating Centre for Drug Statistics Methodology. Defined daily dose (DDD). Guidelines for ATC classification and DDD assignment. https:\/\/www.who.int\/tools\/atc-ddd-toolkit\/about-ddd. Accessed 22 Jan 2024."},{"issue":"17","key":"709_CR22","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.1001\/jama.2021.13338","volume":"326","author":"AW Mulcahy","year":"2021","unstructured":"Mulcahy AW, Schwam D, Rao P, Rennane S, Shetty K. Estimated savings from international reference pricing for prescription drugs. JAMA. 2021;326(17):1744\u20135. https:\/\/doi.org\/10.1001\/jama.2021.13338.","journal-title":"JAMA"},{"issue":"3","key":"709_CR23","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s40259-023-00589-3","volume":"37","author":"K Peng","year":"2023","unstructured":"Peng K, Blais JE, Pratt NL, et al. Impact of introducing infliximab biosimilars on total infliximab consumption and originator infliximab prices in eight regions: an interrupted time-series analysis. BioDrugs. 2023;37(3):409\u201320. https:\/\/doi.org\/10.1007\/s40259-023-00589-3.","journal-title":"BioDrugs"},{"key":"709_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.102005","author":"C Habashy","year":"2023","unstructured":"Habashy C, Yemeke TT, Bolous NS, et al. Variations in global prices of chemotherapy for childhood cancer: a descriptive analysis. eClinicalMedicine. 2023. https:\/\/doi.org\/10.1016\/j.eclinm.2023.102005.","journal-title":"eClinicalMedicine."},{"issue":"1","key":"709_CR25","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1186\/s12902-021-00798-3","volume":"21","author":"N Mardetko","year":"2021","unstructured":"Mardetko N, Nabergoj Makovec U, Locatelli I, Janez A, Kos M. Uptake of new antidiabetic medicines in 11 European countries. BMC Endocr Disord. 2021;21(1):127. https:\/\/doi.org\/10.1186\/s12902-021-00798-3.","journal-title":"BMC Endocr Disord"},{"issue":"4","key":"709_CR26","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s40265-023-01837-0","volume":"83","author":"VKC Yan","year":"2023","unstructured":"Yan VKC, Li HL, Wei L, Knapp MRJ, Wong ICK, Chan EW. Evolving trends in consumption of direct oral anticoagulants in 65 countries\/regions from 2008 to 2019. Drugs. 2023;83(4):315\u201340. https:\/\/doi.org\/10.1007\/s40265-023-01837-0.","journal-title":"Drugs"},{"issue":"10","key":"709_CR27","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1007\/s00228-021-03155-4","volume":"77","author":"S Azuz","year":"2021","unstructured":"Azuz S, Newton M, Bartels D, Poulsen BK. Uptake of biosimilar trastuzumab in Denmark compared with other European countries: a comparative study and discussion of factors influencing implementation and uptake of biosimilars. Eur J Clin Pharmacol. 2021;77(10):1495\u2013501. https:\/\/doi.org\/10.1007\/s00228-021-03155-4.","journal-title":"Eur J Clin Pharmacol"},{"issue":"2","key":"709_CR28","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.ando.2020.12.009","volume":"82","author":"C Le Pen","year":"2021","unstructured":"Le Pen C, Bauduceau B, Ansolabehere X, et al. Penetration rates of new pharmaceutical products in Europe: a comparative study of several classes recently launched in type-2 diabetes. Annales d\u2019Endocrinologie. 2021;82(2):99\u2013106. https:\/\/doi.org\/10.1016\/j.ando.2020.12.009.","journal-title":"Annales d\u2019Endocrinologie."},{"key":"709_CR29","doi-asserted-by":"publisher","unstructured":"OECD. Inflation (CPI) (indicator). Published online 2024. https:\/\/doi.org\/10.1787\/eee82e6e-en.","DOI":"10.1787\/eee82e6e-en"},{"key":"709_CR30","unstructured":"Piedade D, Verhelst H. Market review\u2014biosimilar medicine markets 2020. Medicines for Europe; 2021. https:\/\/www.medicinesforeurope.com\/biosimilar-medicines\/whats-new\/. Accessed 19 Dec 2022."},{"key":"709_CR31","doi-asserted-by":"crossref","unstructured":"Vogler S, Schneider P, Zuba M, Busse R, Panteli D. Policies to encourage the use of biosimilars in European countries and their potential impact on pharmaceutical expenditure. Front Pharmacol. 2021;12. https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.625296. Accessed 15 Dec 2022.","DOI":"10.3389\/fphar.2021.625296"},{"issue":"6","key":"709_CR32","doi-asserted-by":"publisher","first-page":"499","DOI":"10.3390\/ph14060499","volume":"14","author":"L Barbier","year":"2021","unstructured":"Barbier L, Simoens S, Soontjens C, Claus B, Vulto AG, Huys I. Off-patent biologicals and biosimilars tendering in Europe\u2014a proposal towards more sustainable practices. Pharmaceuticals. 2021;14(6):499. https:\/\/doi.org\/10.3390\/ph14060499.","journal-title":"Pharmaceuticals"},{"issue":"1","key":"709_CR33","doi-asserted-by":"publisher","first-page":"1705120","DOI":"10.1080\/20016689.2019.1705120","volume":"8","author":"S Simoens","year":"2020","unstructured":"Simoens S, Cheung R. Tendering and biosimilars: what role for value-added services? J Mark Access Health Policy. 2020;8(1):1705120. https:\/\/doi.org\/10.1080\/20016689.2019.1705120.","journal-title":"J Mark Access Health Policy."},{"issue":"15","key":"709_CR34","doi-asserted-by":"publisher","first-page":"E556","DOI":"10.1503\/cmaj.211478","volume":"194","author":"AR McClean","year":"2022","unstructured":"McClean AR, Law MR, Harrison M, Bansback N, Gomes T, Tadrous M. Uptake of biosimilar drugs in Canada: analysis of provincial policies and usage data. CMAJ. 2022;194(15):E556\u201360. https:\/\/doi.org\/10.1503\/cmaj.211478.","journal-title":"CMAJ"},{"issue":"5","key":"709_CR35","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1007\/s40259-021-00493-8","volume":"35","author":"HM Tolonen","year":"2021","unstructured":"Tolonen HM, Falck J, Kurki P, et al. Is there any research evidence beyond surveys and opinion polls on automatic substitution of biological medicines? A systematic review. BioDrugs. 2021;35(5):547\u201361. https:\/\/doi.org\/10.1007\/s40259-021-00493-8.","journal-title":"BioDrugs"},{"key":"709_CR36","doi-asserted-by":"crossref","unstructured":"Moorkens E, Godman B, Huys I, et al. The expiry of Humira\u00ae market exclusivity and the entry of adalimumab biosimilars in Europe: an overview of pricing and national policy measures. Front Pharmacol. 2021;11. https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2020.591134. Accessed 22 Jan 2024.","DOI":"10.3389\/fphar.2020.591134"},{"key":"709_CR37","unstructured":"\"Prescribing \u201ccheap\u201d\u2014INAMI. https:\/\/www.riziv.fgov.be\/fr\/professionnels\/sante\/medecins\/soins\/Pages\/prescrire-bon-marche-20150101.aspx#Pourcentages_de_prescription_%C3%A0_atteindre_par_discipline. Accessed 6 Jan 2023."},{"key":"709_CR38","doi-asserted-by":"publisher","first-page":"573","DOI":"10.2147\/CEOR.S140063","volume":"9","author":"G Dranitsaris","year":"2017","unstructured":"Dranitsaris G, Jacobs I, Kirchhoff C, Popovian R, Shane LG. Drug tendering: drug supply and shortage implications for the uptake of biosimilars. CEOR. 2017;9:573\u201384. https:\/\/doi.org\/10.2147\/CEOR.S140063.","journal-title":"CEOR."},{"key":"709_CR39","unstructured":"Wangen AK, Pettersen MS. Perceptions of non-price criteria in pharmaceutical tenders\u202f: a case study on the Norwegian Market for generic antibiotics. Master thesis. Handelsh\u00f8yskolen BI; 2022. https:\/\/biopen.bi.no\/bi-xmlui\/handle\/11250\/3035690. Accessed 23 Feb 2024."},{"key":"709_CR40","unstructured":"Pharmaceutical strategy of the Norwegian Hospital Procurement Trust. Joint Nordic Specifications Regarding L01BA01 Methotrexate. https:\/\/www.sykehusinnkjop.no\/49612e\/siteassets\/dokumenter\/legemidler\/joint-nordic-procurement\/2020-2.620.b--draft-joint-nordic-tender-specifications.pdf. Accessed 10 May 2024."},{"key":"709_CR41","unstructured":"PEREZ LOPEZ, Mulaku, Romanelli, Ribeiro. Assessment of tender adjudication criteria among European and leading emerging markets. https:\/\/www.ispor.org\/docs\/default-source\/euro2021\/tender-adjudication-criteriaispor-nov-2021e-poster-pdf.pdf?sfvrsn=bab96ad5_0. Accessed 23 Feb 2024."},{"key":"709_CR42","unstructured":"Etanercept biosimilars delayed until 2029 in US. https:\/\/www.gabionline.net\/biosimilars\/news\/etanercept-biosimilars-delayed-until-2029-in-us. Accessed 10 May 2024."},{"key":"709_CR43","unstructured":"Zamecnik A. Humira biosimilars set the stage for long-awaited 2023 US launches. Pharmaceutical Technology. December 5, 2022. https:\/\/www.pharmaceutical-technology.com\/features\/humira-biosimilars-set-the-stage-for-long-awaited-2023-us-launches\/. Accessed 10 May 2024."},{"issue":"7","key":"709_CR44","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1002\/art.41277","volume":"72","author":"JF Baker","year":"2020","unstructured":"Baker JF, Leonard CE, Re VL, Weisman MH, George MD, Kay J. Brief report: biosimilar uptake in the Academic and Veterans Health Administration settings: influence of institutional incentives. Arthritis Rheumatol. 2020;72(7):1067\u201371. https:\/\/doi.org\/10.1002\/art.41277.","journal-title":"Arthritis Rheumatol"},{"issue":"10","key":"709_CR45","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1080\/14712598.2024.2400523","volume":"24","author":"S Thongpooswan","year":"2024","unstructured":"Thongpooswan S, Das A, Patil P, Latymer M, Llamado L, Wee J. Physicians\u2019 and patients\u2019 perception of biosimilars and factors affecting biosimilar prescribing in selected Asian countries: a survey study. Expert Opin Biol Ther. 2024;24(10):1171\u201382. https:\/\/doi.org\/10.1080\/14712598.2024.2400523.","journal-title":"Expert Opin Biol Ther"},{"issue":"1","key":"709_CR46","doi-asserted-by":"publisher","first-page":"102","DOI":"10.18553\/jmcp.2019.25.1.102","volume":"25","author":"E Leonard","year":"2019","unstructured":"Leonard E, Wascovich M, Oskouei S, Gurz P, Carpenter D. Factors affecting health care provider knowledge and acceptance of biosimilar medicines: a systematic review. JMCP. 2019;25(1):102\u201312. https:\/\/doi.org\/10.18553\/jmcp.2019.25.1.102.","journal-title":"JMCP."},{"issue":"4","key":"709_CR47","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1016\/j.xphs.2021.02.003","volume":"110","author":"J Coghlan","year":"2021","unstructured":"Coghlan J, He H, Schwendeman AS. Overview of Humira\u00ae biosimilars: current European landscape and future implications. J Pharm Sci. 2021;110(4):1572\u201382. https:\/\/doi.org\/10.1016\/j.xphs.2021.02.003.","journal-title":"J Pharm Sci"},{"issue":"1","key":"709_CR48","doi-asserted-by":"publisher","first-page":"48","DOI":"10.3390\/pharmaceutics13010048","volume":"13","author":"I Gherghescu","year":"2021","unstructured":"Gherghescu I, Delgado-Charro MB. The biosimilar landscape: an overview of regulatory approvals by the EMA and FDA. Pharmaceutics. 2021;13(1):48. https:\/\/doi.org\/10.3390\/pharmaceutics13010048.","journal-title":"Pharmaceutics"},{"key":"709_CR49","unstructured":"Troein P, Newton M, Stoddart K, Arias A. The impact of biosimilar competition in Europe."},{"key":"709_CR50","unstructured":"Wilsdon T, Pistollato M, Ross-Stewart K, et al. Biosimilars: A global roadmap for policy sustainability. Charles River Associates; 2022. https:\/\/www.organon.com\/australia\/wp-content\/uploads\/sites\/16\/2022\/09\/Biosimilars-A-global-roadmap-for-policy-sustainability-April-2022.pdf."},{"issue":"12","key":"709_CR51","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.3390\/ph5121393","volume":"5","author":"B Calo-Fern\u00e1ndez","year":"2012","unstructured":"Calo-Fern\u00e1ndez B, Mart\u00ednez-Hurtado JL. Biosimilars: company strategies to capture value from the biologics market. Pharmaceuticals. 2012;5(12):1393\u2013408. https:\/\/doi.org\/10.3390\/ph5121393.","journal-title":"Pharmaceuticals"},{"key":"709_CR52","unstructured":"Choosing between available adalimumab products. SPS\u2014Specialist Pharmacy Service. February 22, 2023. https:\/\/www.sps.nhs.uk\/articles\/choosing-between-available-adalimumab-products\/. Accessed 30 Apr 2024."},{"issue":"1","key":"709_CR53","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s12961-023-01015-4","volume":"21","author":"Y Vandenplas","year":"2023","unstructured":"Vandenplas Y, Simoens S, Van Wilder P, Vulto AG, Huys I. The impact of policy interventions to promote the uptake of biosimilar medicines in Belgium: a nationwide interrupted time series analysis. Health Res Policy Sys. 2023;21(1):68. https:\/\/doi.org\/10.1186\/s12961-023-01015-4.","journal-title":"Health Res Policy Sys."},{"key":"709_CR54","unstructured":"Tenders for Drugs & Pharmaceutical Products\u2014Australian Tenders. https:\/\/www.australiantenders.com.au\/tenders\/category\/drugs-pharmaceutical-products. Accessed 30 Aug 2023."},{"key":"709_CR55","unstructured":"First New Brand Price Reductions. Pharmaceutical Benefits Scheme (PBS). https:\/\/www.pbs.gov.au\/info\/industry\/pricing\/pbs-items\/first-new-brand-price-reductions. Accessed 23 July2023."},{"key":"709_CR56","unstructured":"International policies on the appropriate use of biosimilar drugs. CADTH; 2018."},{"key":"709_CR57","unstructured":"Biosimilar Uptake Drivers. Australian Government Department of Health. https:\/\/www.pbs.gov.au\/general\/biosimilars\/biosimilar-uptake-drivers-q-and-a.docx#:~:text=The%20uptake%20drivers%20are%20expected,Health%20for%20each%20affected%20medicine. Accessed 1 Aug 2023."},{"key":"709_CR58","doi-asserted-by":"publisher","DOI":"10.1016\/j.rcsop.2021.100084","volume":"4","author":"I Arnet","year":"2021","unstructured":"Arnet I, Verbeek M, Almarsd\u00f3ttir Anna B, et al. Community pharmacists\u2019 preparedness for substituting biologics and dispensing biosimilars\u2014lessons learned from a multinational survey. Explor Res Clin Soc Pharm. 2021;4: 100084. https:\/\/doi.org\/10.1016\/j.rcsop.2021.100084.","journal-title":"Explor Res Clin Soc Pharm."},{"key":"709_CR59","unstructured":"Pharmaceutical Benefits Scheme (PBS) | About the PBS. Australian Government Department of Health and Aged Care. https:\/\/www.pbs.gov.au\/info\/about-the-pbs. Accessed 7 Aug 2023."},{"key":"709_CR60","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.625296","volume":"12","author":"S Vogler","year":"2021","unstructured":"Vogler S, Schneider P, Zuba M, Busse R, Panteli D. Policies to encourage the use of biosimilars in European Countries and their potential impact on pharmaceutical expenditure. Front Pharmacol. 2021;12: 625296. https:\/\/doi.org\/10.3389\/fphar.2021.625296.","journal-title":"Front Pharmacol"},{"key":"709_CR61","unstructured":"Prescrire \u00ab\u202fbon march\u00e9. Institut national d\u2019assurance maladie-invalidit\u00e9. https:\/\/www.riziv.fgov.be\/fr\/professionnels\/professionnels-de-la-sante\/medecins\/soins-par-le-medecin\/-prescrire-bon-marche-#Pourcentages_de_prescription_%C3%A0_atteindre_par_discipline. Accessed 5 Jan 2023."},{"key":"709_CR62","unstructured":"Commissioning Framework for Biological Medicines (Including Biosimilar Medicines). NHS England; 2017. https:\/\/www.england.nhs.uk\/wp-content\/uploads\/2017\/09\/biosimilar-medicines-commissioning-framework.pdf. Accessed 14 Dec 2022."},{"key":"709_CR63","unstructured":"Country scorecards for biosimilar sustainability. IQVIA Institute for Human Data Science; 2020. https:\/\/www.iqvia.com\/-\/media\/iqvia\/pdfs\/institute-reports\/country-scorecards-for-biosimilar-sustainability\/iqvia-institute-scorecards-appendix-orb2520.pdf. Accessed 26 Mar 2023."},{"key":"709_CR64","unstructured":"Trinnpris\u2014ikke-patenterte legemidler. Norwegian Medical Products Agency. August 15, 2016. https:\/\/www.dmp.no\/offentlig-finansiering\/pris-pa-legemidler\/trinnpris. Accessed 18 July 2023."},{"key":"709_CR65","unstructured":"Biotilsvarende legemidler kan byttes i apotek. Norwegian Medical Products Agency. May 25, 2021. https:\/\/www.dmp.no\/nyheter\/biotilsvarende-legemidler-kan-byttes-i-apotek. Accessed 24 July 2023."},{"key":"709_CR66","unstructured":"Switching between a reference product and a biosimilar. Norwegian Medical Products Agency. October 29, 2017. https:\/\/www.dmp.no\/en\/news\/switching-between-a-reference-product-and-a-biosimilar. Accessed 19 July 2023."},{"key":"709_CR67","unstructured":"The Pharma Legal Handbook: Norway. PharmaBoardroom. https:\/\/pharmaboardroom.com\/legal-reports\/the-pharma-legal-handbook-norway\/. Accessed 7 Aug 2023."},{"key":"709_CR68","unstructured":"Questions and answers on the authorisation of biosimilars. Swissmedic. https:\/\/www.swissmedic.ch\/swissmedic\/en\/home\/services\/documents\/faq_zl_biosimilar.html. Accessed 19 July 2023."},{"key":"709_CR69","unstructured":"Health insurance: co-payment for persons resident in Switzerland. Federal Office of Public Health FOPH. https:\/\/www.bag.admin.ch\/bag\/en\/home\/versicherungen\/krankenversicherung\/krankenversicherung-versicherte-mit-wohnsitz-in-der-schweiz\/praemien-kostenbeteiligung\/kostenbeteiligung.html. Accessed 19 July 2023."},{"key":"709_CR70","unstructured":"FOPH FO of PH. Differentiated cost shares for medicines. https:\/\/www.bag.admin.ch\/bag\/en\/home\/versicherungen\/krankenversicherung\/krankenversicherung-leistungen-tarife\/Arzneimittel\/Differenzierter-Selbstbehalt-bei-Arzneimitteln.html. Accessed 24 July 2023."},{"key":"709_CR71","unstructured":"Yumoto T. Update of drug pricing system in Japan. Ministry of Health, Labour and Welfare. https:\/\/www.pmda.go.jp\/files\/000226220.pdf. Accessed 1 May 2023."},{"issue":"11","key":"709_CR72","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.00970","volume":"2020","author":"Y Kim","year":"2020","unstructured":"Kim Y, Kwon HY, Godman B, Moorkens E, Simoens S, Bae S. Frontiers | Uptake of biosimilar infliximab in the UK, France, Japan, and Korea: budget savings or market expansion across countries? Front Pharmacol. 2020;2020(11): 529600. https:\/\/doi.org\/10.3389\/fphar.2020.00970.","journal-title":"Front Pharmacol"},{"key":"709_CR73","unstructured":"Kim M, Monnard A, Santos da Silva J. The potential for growth in Japan\u2019s biosimilars market | McKinsey. McKinsey & Company. September 20, 2019. https:\/\/www.mckinsey.com\/industries\/life-sciences\/our-insights\/understanding-the-opportunity-in-japans-biosimilar-market. Accessed 1 May 2023."}],"container-title":["BioDrugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-025-00709-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40259-025-00709-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-025-00709-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T11:27:05Z","timestamp":1745580425000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40259-025-00709-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,25]]},"references-count":73,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["709"],"URL":"https:\/\/doi.org\/10.1007\/s40259-025-00709-1","relation":{},"ISSN":["1173-8804","1179-190X"],"issn-type":[{"value":"1173-8804","type":"print"},{"value":"1179-190X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,25]]},"assertion":[{"value":"3 February 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was funded by the Canadian Institutes of Health Research Project Grant (PJT-178132). Wei Zhang has received salary support through a Michael Smith Health Research BC Scholar Award (#18286). Sang-Cheol Bae is supported in part by the Basic Science Research Program, through the National Research Foundation of Korea (NRF), funded by the Ministry of Education (NRF-2021R1A6A1A03038899). The funders had no role in the study design, data collection, analysis, interpretation, or decision to publish.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Wei Zhang is leading a project on an entirely different topic that is funded by a grant-in-aid from Pfizer Canada. The University of British Columbia is the grant recipient. All other authors have no competing interests to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Ethical approval was not required for this study of sales data and published literature.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Data were obtained under license from IQVIA. The data cannot be publicly shared as per a signed agreement. Requests for data can be sent to IQVIA Canada. Published policy literature is cited within the article and can be identified in the reference list.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and materials"}},{"value":"The software application code is not publicly available. As the software application code used to analyze sales data references data obtained under license from IQVIA, limited code may be available upon reasonable request to the corresponding author.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"WZ, AHA, DG, and NB substantially contributed to the conception and design of the work. WZ, AHA, and S-CB substantially contributed to the acquisition of the data. DG, ACTT, and JB substantially contributed to the analysis of the data. All authors substantially contributed to the interpretation of the data. ACTT, JB, and WZ drafted the work. All authors reviewed and revised it critically for important intellectual content. All authors provided final approval of the version to be published and agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"This article is based on internal analysis by the authors using IQVIA MIDAS quarterly sales data for 2012\u20132023, which were obtained under license from IQVIA and reflect estimates of marketplace activity. Copyright IQVIA. All rights reserved. The statements, findings, conclusions, views, and opinions contained and expressed herein are not necessarily those of IQVIA.","order":10,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimer"}}]}}